Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952376 · ClinicalTrials.gov registry record · NA
Equitable Access to COVID-19 Vaccines
A NA study of COVID-19, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 1,722
- Enrollment target
- 1
- Study location
NCT04952376: Completed NA study of COVID-19, sponsored by Mayo Clinic.
NCT04952376 is a NA study of COVID-19 that has completed, run by Mayo Clinic. The registered enrollment target is 1,722 participants, below the 38,459-participant average among 298 other COVID-19 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04952376, a NA study of COVID-19, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,722 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will deploy a multimodal pragmatic intervention to improve vaccine uptake in priority populations and address vaccine hesitancy to improve access by using a proactive organized population-based outreach leveraging health information technology with tailored navigation support to address mistrust and social barriers.
Primary Outcome
Primary outcome will be the receipt of the first dose of any of the COVID-19 vaccines with FDA emergency use authorization
Conditions Studied
Interventions
- BEHAVIORAL SMS delivery of information
- BEHAVIORAL Personalized text message delivery of information
- BEHAVIORAL Interactive or 2-way SMS delivery of information
Study Locations (1)
Arizona
- Mayo Clinic - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,722 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2021-06-10 |
| Phase | NA |
What the finished NCT04952376 record still lists
NCT04952376 is an interventional study that assigns participants to a tested intervention. Its 1,722 participants enrollment target places it among the larger protocols in the corpus, below the 38,459-participant average among 298 other COVID-19 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which SMS delivery of information is the first listed.
NCT04952376 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT04952376 about?
NCT04952376 is a clinical study titled "Equitable Access to COVID-19 Vaccines". This study will deploy a multimodal pragmatic intervention to improve vaccine uptake in priority populations and address vaccine hesitancy to improve access by using a proactive organized population-based outreach leveraging health information technology with tailored navigation support to address m...
What is the current status of trial NCT04952376?
This trial is currently completed. It is a NA study. The enrollment target is 1,722 participants. The study started on 2021-04-01. Estimated completion is 2021-06-10.
What conditions does trial NCT04952376 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04952376?
The interventions under investigation include: SMS delivery of information (BEHAVIORAL), Personalized text message delivery of information (BEHAVIORAL), Interactive or 2-way SMS delivery of information (BEHAVIORAL).
Who is sponsoring clinical trial NCT04952376?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04952376 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04952376's enrollment target sits among peer trials
1,722 52nd of 298 higher than 247 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT06413420 · 1,731 participants
SUNOSI® (Solriamfetol) Pregnancy Registry
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI